RNA
Therapeutics
Introduction
RNA therapeutics offer huge potential as a programmable therapeutic platform which can treat diseases by modulating protein expression. We are developing a new series of modifications and bioconjugation strategies to develop next-generation RNA therapeutics to expand the aperture of diseases, ranging from neurodegenerative diseases through to cancer.
RNA splicing is an extraordinary process that generates protein diversity (i.e., up to 150 000 proteins) from approximately 20,000 human genes. The outcome of splicing is controlled by the spliceosome, a multi-megadalton molecular machine which removes non-protein-coding introns from pre-mRNA and joins protein-coding exons to produce mature mRNA and a lariat structure (Figure 1). Almost all our protein-coding genes express more than one mature mRNA sequence (isoform); many of which encode unique proteins. The corresponding protein isoforms often differ in only small blocks of RNA sequence, yet these small changes completely alter the function of these proteins. We are developing new molecular approaches to study how cells use splicing to control gene expression. These approaches are also being harnessed for the development of therapeutics which alter the outcome of splicing in neurodegenerative diseases and cancer.
Related Publications
111.
Biocatalytic Synthesis of Ribonucleoside Analogues Using Nucleoside Transglycosylase-2
76.
PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
75.
Structural and Kinetic Profiling of Allosteric Modulation of Duplex DNA Induced by DNA-Binding Polyamide Analogues
55.
Identification of G-quadruplexes in long functional RNAs using 7-deazaguanine RNA
54.
Long-Range Vibrational Dynamics Are Directed by Watson–Crick Base Pairing in Duplex DNA
53.
Chemoselective Sequential Click Ligations Directed by Enhanced Reactivity of an Aromatic Ynamine
52.
DNA-directed spatial assembly of photosynthetic light-harvesting proteins
45.
A Targeted Oligonucleotide Enhancer of SMN2 Exon 7 Splicing Forms Competing Quadruplex and Protein Complexes in Functional Conditions
38.
Conjugation of PEG and gold nanoparticles to increase the accessibility and valency of tethered RNA splicing enhancers